|
US5882914A
(en)
*
|
1995-06-06 |
1999-03-16 |
The Johns Hopkins University School Of Medicine |
Nucleic acids encoding the hypoxia inducible factor-1
|
|
AU8536998A
(en)
*
|
1997-06-10 |
1998-12-30 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
|
|
US7973156B2
(en)
|
1997-08-21 |
2011-07-05 |
Quark Pharmaceuticals Inc. |
Hypoxia-regulated genes
|
|
US7074895B2
(en)
|
1997-08-21 |
2006-07-11 |
Quark Biotech, Inc. |
Sequences characteristic of hypoxia-regulated gene transcription
|
|
WO1999009046A1
(en)
|
1997-08-21 |
1999-02-25 |
Quark Biotech, Inc. |
Hypoxia-regulated genes
|
|
AU757930B2
(en)
|
1997-12-01 |
2003-03-13 |
Roche Diagnostics Gmbh |
Optimization of cells for endogenous gene activation
|
|
AU749467B2
(en)
*
|
1997-12-04 |
2002-06-27 |
Genzyme Corporation |
Compositions and methods for inducing gene expression
|
|
WO1999048916A2
(en)
*
|
1998-03-27 |
1999-09-30 |
The Board Of Trustees Of The Leland Stanford Jr. University |
Hypoxia-inducible human genes, proteins, and uses thereof
|
|
US6124131A
(en)
|
1998-08-25 |
2000-09-26 |
The Johns Hopkins University School Of Medicine |
Mutant hypoxia inducible factor-1 HIF-1
|
|
CA2341518A1
(en)
*
|
1998-08-27 |
2000-03-09 |
Quark Biotech, Inc. |
Hypoxia regulated genes
|
|
US6436654B1
(en)
*
|
1998-11-13 |
2002-08-20 |
Pharmacia & Upjohn Ab |
Methods for identifying compounds that modulate HIF-1α
|
|
SE9803891D0
(sv)
*
|
1998-11-13 |
1998-11-13 |
Pharmacia & Upjohn Ab |
Protein Variants
|
|
JP4638098B2
(ja)
*
|
1999-06-14 |
2011-02-23 |
キャンサー・リサーチ・テクノロジー・リミテッド |
癌治療
|
|
WO2001023426A2
(en)
*
|
1999-09-30 |
2001-04-05 |
Varian Associates, Inc. |
Hypoxia-related human genes, proteins, and uses thereof
|
|
FR2801319A1
(fr)
*
|
1999-11-18 |
2001-05-25 |
Inst Nat Sante Rech Med |
Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
|
|
US6893867B1
(en)
|
1999-12-23 |
2005-05-17 |
Keith A. Webster |
Molecular switch for regulating mammalian gene expression
|
|
CN1425075A
(zh)
*
|
2000-02-22 |
2003-06-18 |
牛津生物医学（英国）有限公司 |
差异表达筛选方法
|
|
AU2001290179B2
(en)
*
|
2000-08-07 |
2007-07-12 |
Angiogenetics Sweden Ab |
Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
|
|
US7285414B2
(en)
*
|
2000-09-26 |
2007-10-23 |
Emory University |
Viruses targeted to hypoxic cells and tissues
|
|
US20040101825A1
(en)
*
|
2001-09-26 |
2004-05-27 |
Van Meir Erwin G. |
Viruses targeted to hypoxic cells and tissues
|
|
US7105656B2
(en)
*
|
2000-10-26 |
2006-09-12 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating hematologic malignancies and multiple drug resistance
|
|
US7919274B2
(en)
|
2001-03-20 |
2011-04-05 |
Dana-Farber Cancer Institute, Inc. |
Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
|
|
US6849718B2
(en)
*
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
|
US7176345B2
(en)
*
|
2001-03-20 |
2007-02-13 |
Dana-Farber Cancer Institute, Inc. |
Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
|
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
|
US6660737B2
(en)
|
2001-05-04 |
2003-12-09 |
The Procter & Gamble Company |
Medicinal uses of hydrazones
|
|
US6878729B2
(en)
|
2001-05-04 |
2005-04-12 |
The Procter & Gamble Company |
Medicinal uses of dihydropyrazoles
|
|
WO2002094862A2
(en)
*
|
2001-05-23 |
2002-11-28 |
Angiogene Inc. |
Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
|
|
DE60232443D1
(de)
*
|
2001-06-05 |
2009-07-09 |
Masahiro Hiraoka |
Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
|
|
US6838430B2
(en)
|
2001-09-28 |
2005-01-04 |
The Regents Of The University Of California |
Use of HIF-1a variants to accelerate wound healing
|
|
FR2832154B1
(fr)
|
2001-11-09 |
2007-03-16 |
Centre Nat Rech Scient |
Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
|
|
AU2003208684A1
(en)
*
|
2002-03-05 |
2003-09-16 |
Angiogenetics Sweden Ab |
Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
|
|
ES2649817T3
(es)
*
|
2002-04-05 |
2018-01-15 |
Roche Innovation Center Copenhagen A/S |
Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
|
|
CA2482904A1
(en)
*
|
2002-04-18 |
2003-10-23 |
Lynkeus Biotech Gmbh |
Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
|
|
NZ520321A
(en)
*
|
2002-07-19 |
2005-03-24 |
Auckland Uniservices Ltd |
Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
KR20120038546A
(ko)
*
|
2002-11-01 |
2012-04-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
|
|
US7144999B2
(en)
*
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
|
US20050014264A1
(en)
*
|
2002-12-11 |
2005-01-20 |
University Of Massachusetts |
Method of introducing siRNA into adipocytes
|
|
WO2004066949A2
(en)
|
2003-01-28 |
2004-08-12 |
Rexahn Corporation |
Antisense oligonucleotides that inhibit expression of hif-1
|
|
ES2333794T3
(es)
*
|
2003-01-31 |
2010-03-01 |
Rexahn Pharmaceuticals, Inc. |
Oligonucleotidos que inhiben la expresion de hif-1.
|
|
JP2007512369A
(ja)
*
|
2003-11-26 |
2007-05-17 |
エンテロス・インコーポレーテッド |
低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
|
|
WO2005056795A2
(en)
*
|
2003-12-03 |
2005-06-23 |
Corgentech, Inc. |
Hif oligonucleotide decoy molecules
|
|
US20060003961A1
(en)
*
|
2004-06-18 |
2006-01-05 |
The John Hopkins University |
Negative regulation of hypoxia inducible factor 1 by OS-9
|
|
NZ555644A
(en)
|
2004-11-09 |
2009-04-30 |
Santaris Pharma As |
Potent LNA oligonucleotides for the inhibition of HIF-1A expression
|
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
|
KR100859506B1
(ko)
*
|
2005-07-22 |
2008-09-22 |
한국과학기술연구원 |
프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
|
|
CN100418574C
(zh)
*
|
2005-10-26 |
2008-09-17 |
王成球 |
一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
|
|
US20070122448A1
(en)
*
|
2005-11-28 |
2007-05-31 |
Alireza Rezania |
Compositions and methods to create a vascularized environment for cellular transplantation
|
|
ES2596885T3
(es)
|
2006-06-07 |
2017-01-12 |
Genzyme Corporation |
Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la medula espinal
|
|
JP2009540011A
(ja)
*
|
2006-06-12 |
2009-11-19 |
エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． |
血管新生のｓｉＲＮＡ阻害のための組成物及び方法
|
|
US20080119433A1
(en)
*
|
2006-07-06 |
2008-05-22 |
Aaron Thomas Tabor |
Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
|
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
|
SI2497500T1
(sl)
|
2006-10-03 |
2017-01-31 |
Genzyme Corporation |
Genska terapija za spinalno mišično atrofijo
|
|
NZ598092A
(en)
*
|
2008-02-14 |
2012-07-27 |
Lincoln University |
Methods and compositions comprising specific strains of trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
|
|
MX2011005851A
(es)
|
2008-12-04 |
2011-07-29 |
Opko Opthalmics Llc |
Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
|
|
RS67077B1
(sr)
|
2009-05-02 |
2025-08-29 |
Genzyme Corp |
Genska terapija za neurodegenerativne poremećaje
|
|
EP4219708A3
(en)
|
2009-07-17 |
2023-10-11 |
Aaron Thomas Tabor |
Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
|
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
|
US9446031B2
(en)
|
2012-01-18 |
2016-09-20 |
National University Of Singapore |
Compositions and methods for neovascularization
|
|
CA2895791A1
(en)
*
|
2013-01-25 |
2014-07-31 |
Xcell Biosciences, Inc. |
Methods, compositions, kits, and systems for selective enrichment of target cells
|
|
JP6836400B2
(ja)
|
2014-03-28 |
2021-03-03 |
ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション |
乳がんおよび卵巣がんワクチン
|
|
GB201601527D0
(en)
|
2016-01-27 |
2016-03-09 |
Univ Southampton |
Hif-1 and Hif-2 inhibitors
|
|
US20230212296A1
(en)
*
|
2020-06-02 |
2023-07-06 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Systems and methods for treating cancer
|
|
CN116024263A
(zh)
*
|
2022-09-23 |
2023-04-28 |
龙岩学院 |
一种高效表达猪HIF-1α基因的真核表达载体及其构建方法
|
|
WO2024211763A1
(en)
*
|
2023-04-05 |
2024-10-10 |
The Johns Hopkins University |
Synthetic mrna encoding hif-1alpha and uses for wound healing
|